Anna Protopapas Mersana Therapeutics, Inc. (MRSN) insider trading activity

Anna Protopapas is Director of Mersana Therapeutics, Inc.. Currently has a direct ownership of 125,153 shares of MRSN, which is worth approximately $202,747. The most recent transaction as insider was on Jan 16, 2024, when has been sold 29,399 shares (Common Stock) at a price of $2.71 per share, resulting in proceeds of $79,671. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 125K

0% 3M change

85.15% 12M change

Total Value Held $202,747

Anna Protopapas Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 16 2024	SELL Open market or private sale	$79,671 $2.71 p/Share	29,399 Reduced 19.02%	125,153 Common Stock
Jan 15 2024	BUY Exercise of conversion of derivative security	-	38,958 Added 20.13%	154,552 Common Stock
Jan 14 2024	BUY Exercise of conversion of derivative security	-	16,750 Added 12.66%	115,594 Common Stock
Jan 13 2024	BUY Exercise of conversion of derivative security	-	31,250 Added 24.02%	98,844 Common Stock
Sep 11 2023	BUY Grant, award, or other acquisition	-	16,643 Added 19.76%	67,594 Common Stock
Jan 17 2023	SELL Open market or private sale	$99,566 $5.74 p/Share	17,346 Reduced 26.25%	48,733 Common Stock
Jan 15 2023	BUY Exercise of conversion of derivative security	-	38,958 Added 37.09%	66,079 Common Stock
Jan 14 2023	BUY Exercise of conversion of derivative security	-	16,750 Added 38.18%	27,121 Common Stock
May 20 2022	SELL Bona fide gift	-	240,244 Reduced 95.86%	10,371 Common Stock
Jan 14 2022	BUY Exercise of conversion of derivative security	-	38,958 Added 10.77%	322,878 Common Stock
Jul 19 2021	SELL Open market or private sale	$263,250 $12.02 p/Share	21,901 Reduced 7.18%	282,978 Common Stock
Jul 16 2021	SELL Open market or private sale	$249,936 $12.47 p/Share	20,043 Reduced 6.17%	304,879 Common Stock
Jul 15 2021	BUY Exercise of conversion of derivative security	-	100,000 Added 23.53%	324,922 Common Stock
Jan 15 2021	SELL Payment of exercise price or tax liability	$109,626 $21.09 p/Share	5,198 Reduced 2.26%	224,922 Common Stock
Jan 15 2021	BUY Exercise of conversion of derivative security	-	17,709 Added 7.15%	230,120 Common Stock

Also insider at

DRNA

Dicerna Pharmaceuticals Inc

Director

NUVL

Nuvalent, Inc. Healthcare

Anna Protopapas

Director

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MRSN shares.

Notify only if

Value

Insider Trading

Get notified when an Mersana Therapeutics, Inc. insider buys or sells MRSN shares.

Notify only if

Operation

Value

Type

News

Receive news related to Mersana Therapeutics, Inc.

Track Activities on MRSN

Account